RE: Potential Investors30 Nov 2023 19:03
A company I believe is set to explode and has the potential to rise significantly in the near term.
What justifies such a bold prediction?
This company may hold the keys to the cure for aging...
The name of the company is Genflow Biosciences and it trades under the ticker (GENF) on the London stock exchange.
Consider that the biotech market is expected to reach USD 2.44 trillion by 2028 and expand at a CAGR of 15.83% until then.*
The demand for longevity is limitless, and the first companies that succeed in supplying the disruptive technologies that unlock it will capture the lion’s share of those trillions.
But before I go any further, let me ask you something…
Have you heard of the freshly minted biotech mega-startup that received $3 billion in backing in a single day?
According to Forbes, Altos Labs likely holds the world record for financing of any start-up by an order of magnitude or more.
With reports of early investments from entrepreneurial juggernaut Jeff Bezos and renowned info-tech investor Yuri Milner, Altos Labs is a likely contender for a top spot in the race to reverse aging and revolutionize medicine.
But backing from big names isn’t the only ace up the sleeve of Altos Labs…
The company has built an executive dream team of industry experts and scientific luminaries.
Among those reported to be joining the ambitious roster is none other than the Nobel prize winner for the discovery of reprogramming.
What is reprogramming and why is it important you might ask?
Shinya Yamanaka won his Nobel prize for discovering how to transform ordinary adult skin cells into any cell in the human body.
Need a new liver? Tired of living with Parkinson’s? Want your eyesight back?
Yamanaka’s research is key to engineering the regenerative medicine that will one day be responsible for replacing and repairing damaged organs and tissues.
With a deluge of capital and a hot shot team to employ it efficiently, Altos Labs is poised to accomplish its mission statement, “to restore cell health and resilience to reverse disease, injury, and disabilities that occur throughout life.”
But what does all of this have to do with Genflow Biosciences potentially significant rise in value?
I’m going to tell you, but first, let’s get some background.
Genflow Biosciences is challenging the aging process with exclusive patents to the leading longevity technology from the University of Rochester (US).
Okay, but why should we expect such sudden exponential growth.
The answer lies in a 2013 paper published in a highly regarded journal entitled “The Hallmarks of Ageing”...
To put it simply, the paper outlines 9 hallmarks of aging that provide a framework for prolonging human life. This roadmap to longevity spawned numerous biotech companies that used it as a roadmap for their R&D.
But even the companies regarded as the cream-of-crop are at a disadvantage…
Sign In
Follow the stocks
